Medicare And Alzheimer’s Drugs: Pressure To Relax Coverage Restrictions Rising Wtih Donanemab Data
Executive Summary
Lilly's donanemab may be the second amyloid-targeting drug for Alzheimer’s headed toward a traditional US Food and Drug Administration approval this year, setting up a showdown with Medicare over its coverage with evidence development requirements.
You may also be interested in...
New Alzheimer’s Drug Access Should Ease Somewhat Under Updated Medicare PET Scan Proposal
After a decade of curtailed use, new drugs make wider availability important for patient selection and safety, CMS says in a new amyloid PET scan proposal.
Medicare’s Alzheimer’s Drug Registry: Ease Of Use May Lead To Data Quality Tradeoffs
New details from CMS about the information that providers will be required to submit for Medicare beneficiaries taking anti-amyloid Alzheimer’s drugs indicate the agency could have a hard time getting answers to some of the key questions outlined in its National Coverage Determination.
Medicare Registry Plan For Alzheimer’s Drugs Pairs CMS Web Portal With Health System Efforts
Lack of detail on data elements that would be required through the portal has stakeholders wondering if the Centers for Medicare and Medicaid Services has really found a way to make the registry requirement less of a threat to access for Alzheimer’s drugs with traditional FDA approval.